NRX Pharmaceuticals Inc

Research NRX Pharmaceuticals Inc (NRXP) on Bullrun: market cap USD 158.39M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 158.39M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 1.23M-USD 28.62M-USD 14.11M58.8%-2.93USD 7.80MUSD 631.00K-USD 15.94M
FY2024USD 0-USD 25.13M-USD 10.64Mn/a-4USD 1.44MUSD 6.58M-USD 23.22M
FY2023USD 0-USD 30.15M-USD 21.66Mn/a-22.55USD 4.60MUSD 18.32M-USD 11.73M
FY2022n/a-USD 39.75M-USD 39.77Mn/a-0.6USD 20.05MUSD 10.53MUSD 7.41M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 158.39Mn/an/an/a
20252025-12-31USD 86.00Mn/an/an/a
20242024-12-31USD 32.10Mn/an/an/a
20232023-12-29USD 39.18Mn/an/an/a
20222022-12-30USD 75.08Mn/an/an/a
20212021-12-31USD 281.12Mn/an/an/a

About NRX Pharmaceuticals Inc

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is NRX Pharmaceuticals Inc's market cap?

NRX Pharmaceuticals Inc's market capitalization is USD 158.39M.

What does NRX Pharmaceuticals Inc do?

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments.